Terms ending in 2037
Every in-force patent on Sandoz AG's record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,292,833 | Selective Reduction of Cysteine Residues in IL-17 Antibodies In force · High confidence | Novartis Pharma AG | In force | High confidence | |
| US 10,842,782 | Storage Stable Composition Comprising Rifaximin Alpha In force · High confidence | Sandoz AG | In force | High confidence | |
| US 10,576,065 | Pharmaceutical Composition Containing Rifaximin Alpha & Delta In force · High confidence | Sandoz AG | In force | High confidence | |
| US 10,975,029 | Crystalline Eravacycline Bis-Hydrochloride In force · High confidence | Sandoz AG | In force | High confidence | |
| US 11,124,513 | Avibactam Free Acid In force · High confidence | Sandoz AG | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Sandoz AG.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.